BC
IOVA icon

Broadfin Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Broadfin Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-27,500
Closed -$352K – 52
2018
Q2 		$352K Buy
+27,500
New +$402K 0.06% 45

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Broadfin Capital's IOVA Position: Q4 2019 in Review

Broadfin Capital reduced its Iovance Biotherapeutics (IOVA) stake by 53% in Q4 2019, selling an estimated $13.6M and leaving 533,301 shares worth $14.8M. The position accounts for 1.98% of the portfolio, ranked #16.

Broadfin Capital first reported a position in IOVA in Q1 2015 and has held it in 20 quarters since. The position peaked at $55.1M in Q3 2018. 200 funds tracked by Wall St. Rank hold IOVA as of Q4 2019.

  • Broadfin Capital held 533,301 shares of Iovance Biotherapeutics worth $14.8M as of Q4 2019.
  • Broadfin Capital sold 597,800 Iovance Biotherapeutics shares in Q4 2019, an estimated $13.6M.
  • Iovance Biotherapeutics made up 1.98% of Broadfin Capital's portfolio in Q4 2019, its #16 holding.
  • Broadfin Capital first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 20 quarters since.
  • Broadfin Capital's Iovance Biotherapeutics position peaked at $55.1M in Q3 2018.
  • 200 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.